Gritstone bio Reports Interim Phase 2 Data From Ongoing Phase 2 Study Evaluating GRANITE; Reveals Encouraging Progression-Free Survival Data In Overall Population; Overall Survival Data Expected In 2H 2025
Portfolio Pulse from Benzinga Newsdesk
Gritstone bio has reported promising interim Phase 2 data for its GRANITE immunotherapy in treating microsatellite stable colorectal cancer. The data shows encouraging progression-free survival benefits, with overall survival data expected in the second half of 2025.
September 30, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gritstone bio's interim Phase 2 data for GRANITE shows promising progression-free survival benefits in MSS-CRC, potentially boosting investor confidence.
The positive interim data for GRANITE in a challenging cancer type suggests potential efficacy, which could lead to increased investor confidence and a positive short-term impact on GRTS stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100